Loading...

APC anti-mouse CD86 Antibody

Pricing & Availability
Clone
GL-1 (See other available formats)
Regulatory Status
RUO
Other Names
B7-2, B70, Ly-58
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
GL-1_APC_090707
LPS-stimulated (3 days) C57BL/6 mouse splenocytes stained with GL-1 APC
  • GL-1_APC_090707
    LPS-stimulated (3 days) C57BL/6 mouse splenocytes stained with GL-1 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
105011 25 µg 77€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
105012 100 µg 227€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD86 is an 80 kD immunoglobulin superfamily member also known as B7-2, B70, and Ly-58. CD86 is expressed on activated B and T cells, macrophages, dendritic cells, and astrocytes. CD86, along with CD80, is a ligand of CD28 and CD152 (CTLA-4). CD86 is expressed earlier in the immune response than CD80. CD86 has also been shown to be involved in immunoglobulin class-switching and triggering of NK cell-mediated cytotoxicity. CD86 binds to CD28 to transduce co-stimulatory signals for T cell activation, proliferation, and cytokine production. CD86 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
LPS-activated CBA/Ca mouse splenic B cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The GL-1 antibody can block the mixed lymphocyte reaction in vitro and has been shown to inhibit the priming of cytotoxic T lymphocytes in vivo (along with antibodies against B7-1). Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of acetone-fixed frozen sections2,6, immunofluorescence microscopy, and in vivo and in vitro blocking of T cell responses1-6. GL-1 is not suitable for immunohistochemical staining of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 105051-105056).

Application References
  1. Hathcock KS, et al. 1993. Science 262:905. (Block, IP)
  2. Inaba KM, et al. 1994. J. Exp. Med. 180:1849. (Block, IHC)
  3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
  4. Krummel MF, et al. 1995. J. Exp. Med. 182:459. (Block)
  5. Liu Y, et al. 1997. J. Exp. Med. 185:251. (Block)
  6. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  9. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
  10. Klinger MB, et al. 2007. Am. J. Physiol. Requl. Integr. Comp. Physiol. 293:R677. PubMed
  11. de Verteuil DA, et al. 2014. J Immunol. 193:1121. PubMed
Product Citations
  1. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  2. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  3. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
  4. Arora H, et al. 2019. Immunity. 50:418. PubMed
  5. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  6. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  7. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  8. Verteuil D, et al. 2014. J Immunol. 193:1121. PubMed
  9. Kashyap AS, et al. 2019. Cell Rep. 28:3367. PubMed
  10. Larsen SE, et al. 2021. Sci Rep. 11:9040. PubMed
  11. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  12. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  13. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  14. Cho H, et al. 2022. Nat Commun. 13:5974. PubMed
  15. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  16. Hu M, et al. 2022. Can Respir J. 2022:5802938. PubMed
  17. Wu J, et al. 2021. Mol Med Rep. 23:. PubMed
  18. Sitnik S, et al. 2020. Mol Ther Oncolytics. 17:190. PubMed
  19. Park S, et al. 2021. Nat Cell Biol. 23:476. PubMed
  20. Mul Fedele ML, et al. 2020. Front Cell Infect Microbiol. 10:100. PubMed
  21. Xiao Y, et al. 2019. JCI Insight. 4:e99052. PubMed
  22. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  23. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  24. Zheng Y, et al. 2022. Front Pharmacol. 12:816032. PubMed
  25. Wu L, et al. 2022. Front Cell Dev Biol. 9:684842. PubMed
  26. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  27. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  28. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
  29. Sellau J, et al. 2016. Sci Rep. 6:28058. PubMed
  30. Wang Y, et al. 2021. Cell Rep. 35:108948. PubMed
  31. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  32. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  33. Yu X, et al. 2020. Cancer Cell. 37(6):850-866. PubMed
  34. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  35. Roberts LM, et al. 2021. iScience. 24:103025. PubMed
  36. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  37. Qian J, et al. 2021. Int J Mol Sci. 22:. PubMed
  38. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  39. Zhang X, et al. 2022. JCI Insight. 7:. PubMed
  40. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  41. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  42. Sun S, et al. 2021. Front Immunol. 12:777665. PubMed
  43. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  44. Seki T, et al. 2015. J Biochem. 158: 485 - 495. PubMed
  45. Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed
  46. Yamada KJ, et al. 2020. PLoS Pathog. 16:e1008354. PubMed
  47. Yang C, et al. 2019. Nanomedicine (Lond). 14:2423. PubMed
  48. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  49. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  50. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  51. Qiu N, et al. 2021. J Nanobiotechnology. 19:428. PubMed
  52. Gómez LA, et al. 2020. Front Microbiol. 11:1586. PubMed
  53. Shepherd J 2011. Toxicol Sci. 120:68. PubMed
  54. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  55. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  56. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  57. Li ZL, et al. 2021. Mol Ther Nucleic Acids. 25:502. PubMed
  58. Bi CS, et al. 2020. Cell Prolif. 53:e12827. PubMed
  59. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  60. Lu SW, et al. 2020. Nat Commun. 3.660416667. PubMed
  61. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  62. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  63. Zhao F et al. 2018. Immunity. 48(1):147-160 . PubMed
  64. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  65. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  66. Huang L, et al. 2021. Frontiers in Cellular and Infection Microbiology. 10:606340. PubMed
  67. Zhang W, et al. 2021. Front Immunol. 12:768435. PubMed
  68. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  69. Singhal P, et al. 2016. Proc Natl Acad Sci U S A. 113: 122 - 127. PubMed
  70. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  71. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
  72. Bahmani B, et al. 2021. Nat Commun. 12:1999. PubMed
  73. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  74. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  75. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  76. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  77. Trivedi S, et al. 2020. Elife. 9:00. PubMed
  78. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  79. Finkin S et al. 2019. Immunity. 51(2):324-336 . PubMed
  80. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
RRID
AB_493343 (BioLegend Cat. No. 105011)
AB_493342 (BioLegend Cat. No. 105012)

Antigen Details

Structure
Ig superfamily, 80 kD
Distribution

B cells and T cells (upregulated upon activation), macrophages, dendritic cells, and astrocytes

Function
T cell costimulation, Ig class-switching, NK cell cytotoxicity
Ligand/Receptor
CD28, CD152 (CTLA-4)
Cell Type
Astrocytes, B cells, Dendritic cells, Macrophages, T cells, Tregs
Biology Area
Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Hathcock KS, et al. 1993. Science 262:905.
3. Freeman GJ, et al. 1993. Science 262:907.
4. Carreno BM, et al. 2002. Annu. Rev. Immunol. 20:29.

Gene ID
12524 View all products for this Gene ID
UniProt
View information about CD86 on UniProt.org
Go To Top Version: 1    Revision Date: 11-30-2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account